Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & UniQure

7 shared events · Importance 5 · Last updated Apr 13, 2026

Importance
5
Shared Events
7
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
55
Regulatory
United States — Food and Drug Administration: The FDA is the subject of the restructuring, which could reshape its leadership and regulatory approach, affecting drug approvals and AI oversight.
UniQure: UniQure faced an FDA demand for an extra trial but later was allowed to seek accelerated approval, a positive outcome.
Aug 25, 2026 · 6 articles
39
Domestic
United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.
UniQure: UniQure also benefited from FDA reversals. The new commissioner's stance may impact its gene therapy approvals.
Aug 19, 2026 · 101 articles
0
Regulatory
Nov 14, 2025 · 6 articles
0
Regulatory
UniQure: UniQure is facing a securities class action lawsuit and severe public criticism from the United States — Food and Drug Administration regarding its gene therapy candidate, AMT-130, leading to a significant drop in its stock price.
Mar 10, 2026 · 7 articles
0
Business
UniQure: UniQure is the defendant in a securities fraud class action lawsuit due to alleged material misstatements and omissions regarding its Huntington's disease gene therapy drug, AMT-130, which led to a significant drop in its share price.
Feb 19, 2026 · 6 articles
0
Business
UniQure: UniQure is facing a class action lawsuit for allegedly making false and misleading statements regarding the FDA approval of its Pivotal Study and the potential delay in its Biologics License Application timeline.
Apr 02, 2026 · 20 articles
0
Regulatory
UniQure: UniQure is facing a securities class action lawsuit for allegedly misrepresenting its interactions with the United States — Food and Drug Administration regarding its gene therapy candidate AMT-130, leading to a significant drop in its stock price.
Apr 01, 2026 · 25 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and UniQure interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.